T. Matthews

发表

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

Eric Hunter, Thomas Matthews, M. Nowak, 1998, Nature Medicine.

Synthesis and Processing of Picornaviral Polyprotein

M. Pallansch, R. Rueckert, T. Matthews, 1979 .

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

T. Matthews, C. McDanal, C. Wild, 1994, Proceedings of the National Academy of Sciences of the United States of America.

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.

T. Matthews, C. Wild, T. Greenwell, 1993, AIDS research and human retroviruses.

Evidence of ambiguous processing and selective degradation in the noncapsid proteins of rhinovirus 1A

R. Rueckert, T. Matthews, C. McLean, 1976, Journal of virology.

Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines

M. Skinner, M. Hershfield, J. Leeds, 1988, The Journal of experimental medicine.

Human immunodeficiency virus‐1 disease progression in hemophiliacs

T. Matthews, K. Weinhold, G. White, 1990, American journal of hematology.

Convergent synthesis of a helical, prehairpin HR1 trimer from HIV gp41

T. Matthews, J. J. Dwyer, S. Schneider, 2010, Journal of peptide science : an official publication of the European Peptide Society.

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

A J Langlois, B. Haynes, D. Bolognesi, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Neutralization epitopes of the HIV-1 primary isolate DH012.

T. Matthews, Chin-Ho Chen, Chongbin Zhu, 2003, Vaccine.

Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived from Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-Induced Anti-HIV Neutralizing Antibodies

B. Haynes, M. A. Moody, T. Matthews, 1999, Journal of Virology.

Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.

H. Liao, B. Haynes, J. Robinson, 1997, AIDS research and human retroviruses.

Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine

S. Zolla-Pazner, M. Klein, T. Matthews, 1992, Journal of virology.

Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.

J. Morris, F. Wong-Staal, T. Matthews, 1991, AIDS research and human retroviruses.

HIV-1 neutralizing antibody and approaches to the envelope diversity problem.

S. Buttò, D. Bolognesi, T. Matthews, 1991, Advances in experimental medicine and biology.

Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals.

T. Matthews, W. Kenealy, S. Petteway, 1989, AIDS research and human retroviruses.

Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells.

R. Bell, P. V. Van Veldhoven, D. Bolognesi, 1992, Biochemical and biophysical research communications.

Expression andImmunogenicity oftheExtracellular Domain oftheHumanImmunodeficiency VirusType1 Envelope Glycoprotein, gpl60

G. Nakamura, J. Groopman, T. Matthews, 1989 .

Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding

F. Celada, S. Burastero, T. Matthews, 1990, The Journal of experimental medicine.

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

R. Belshe, B. Graham, P. Wright, 1994, The Journal of infectious diseases.

Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues.

K. Titani, T. Matthews, T. Mizuochi, 1990, The Journal of biological chemistry.

Cellular immune response to viral peptides in patients exposed to HIV.

H. Lyerly, D. Bolognesi, T. Matthews, 1988, AIDS research and human retroviruses.

Immunochemical and biochemical characterization of a glioma‐associated extracellular matrix glycoprotein

S. Pizzo, D. Bigner, T. Matthews, 1985, Journal of cellular biochemistry.

Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses.

R. Snyderman, D. Bolognesi, T. Matthews, 1980, Journal of immunology.

Human immunodeficiency virus type 1 infection of human monocytes and macrophages does not alter their ability to generate an oxidative burst.

T. Matthews, J. Weinberg, C. Dukes, 1993, The Journal of infectious diseases.

Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

L. Hood, J. Mullins, L. Rowen, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

B. Haynes, R. Scearce, D. Bolognesi, 1990, Journal of immunology.

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

R. Belshe, B. Graham, P. Wright, 1993, The Journal of infectious diseases.

Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

R. Belshe, B. Graham, P. Wright, 1993 .

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

Lei Jin, T. Matthews, M. Greenberg, 2004, AIDS.

HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

H. Lyerly, D. Bolognesi, T. Matthews, 1989, Journal of immunology.

Detection of a transformation-specific glycopeptide in SSV-infected cells.

D. Bolognesi, T. Matthews, H. Thiel, 1981, Virology.

Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial

Thomas Matthews, Michael Keefer, M. McElrath, 1996, Annals of Internal Medicine.

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

R. Belshe, L. Corey, P. Berman, 1999, AIDS research and human retroviruses.

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

R. Belshe, L. Corey, M. Eibl, 1998, Vaccine.

Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

D. Stablein, M. McElrath, B. Graham, 1998 .

Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59

D. Stablein, M. McElrath, B. Graham, 1996 .

HIV‐1 recombinant gp160 vaccine given in accelerated dose schedules

D. Stablein, R. Belshe, B. Graham, 1994, Clinical and experimental immunology.

Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection

D. Stablein, W. Koff, R. Belshe, 1993 .

Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.

B. Autran, M. Kieny, J. Excler, 1995, AIDS research and human retroviruses.

Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein

B. Haynes, L. Arthur, R. Scearce, 1993, The Journal of experimental medicine.

The ability of certain SIV vaccines to provoke reactions against normal cells.

D. Bolognesi, T. Matthews, K. Weinhold, 1992, Science.

Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses.

M. Luscher, K. MacDonald, K. Rosenthal, 2003, AIDS research and human retroviruses.

Human T-cell lymphotropic virus I and adult T-cell leukemia: report of a cluster in North Carolina.

B. Haynes, R. Janssen, R. Spiegel, 1988, The American journal of medicine.

HIV vaccines: Viral envelope fails to deliver?

D. Bolognesi, T. Matthews, 1998, Nature.

The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.

T. Matthews, C. Wild, T. Greenwell, 1995, AIDS research and human retroviruses.

Prospects for the immunological management of lethal tumors.

J. Iglehart, D. Bolognesi, T. Matthews, 1983, Cancer investigation.

Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.

D. Bolognesi, T. Matthews, M. Greenberg, 2000, AIDS research and human retroviruses.

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

J. Erickson, D. Lambert, T. Matthews, 2005, Journal of Virology.

Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564

Lei Jin, T. Matthews, Chin-Ho Chen, 2001, Antimicrobial Agents and Chemotherapy.

V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

E. Hunter, J. Morris, L. Gutshall, 1992, Virology.

Prospects for development of a vaccine against HIV-related disorders

H. Lyerly, D. Bolognesi, T. Matthews, 1987 .

Prospects for development of a vaccine against HTLV-III-related disorders.

H. Lyerly, R. Gallo, D. Bolognesi, 1987, AIDS research and human retroviruses.

Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein.

R. Gallo, D. Bolognesi, T. Matthews, 1987, Haematology and blood transfusion.

The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.

T. Matthews, J. White, J. J. Dwyer, 2003, Biochemistry.

Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus.

D. Bolognesi, T. Matthews, K. Weinhold, 1992, AIDS research and human retroviruses.

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

T. Matthews, J. J. Dwyer, M. Greenberg, 2007, Proceedings of the National Academy of Sciences.

Evidence ofAmbiguous Processing and Selective Degradation

R. Rueckert, T. Matthews, C. McLean, 2003 .

Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages

J. Bartlett, D. Bolognesi, T. Matthews, 1991, Journal of virology.

Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain.

E. Reinherz, D. Bolognesi, T. Matthews, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

H. Lyerly, D. Bolognesi, T. Matthews, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens.

D. Tribe, T. Matthews, W. Kenealy, 1987, AIDS research and human retroviruses.

Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides

T. Matthews, D. Shugars, L. Rimsky, 1998, Journal of Virology.

Protection of MN-rgp 120-Immunized Chimpanzees from Heterologous Infection with a Primary Isolate of Human Immunodeficiency Virus Type 1

Krishna, T. Wrin, M. Champe, 2010 .

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

T. Wrin, M. Champe, G. Nakamura, 1996, The Journal of infectious diseases.

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.

D. Stablein, B. Graham, L. Corey, 1996, AIDS research and human retroviruses.

The role of the third β strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012

C. H. Chen, L. Zhu, T. Matthews, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

S. Zolla-Pazner, M. Gorny, D. Tyler, 1990, Journal of immunology.

Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex.

J. White, D. Lambert, T. Matthews, 2000, Biochemistry.

A Peptide Inhibitor of Hiv-1 Replication: Correlation Between Solution Structure and Viral Inhibition

T. Oas, D. Bolognesi, T. Matthews, 1993 .

Using Peptides and Peptide Sera Toward Studying the Principal Neutralization Determination of HIV

T. Matthews, J. Rusche, G. Larosa, 1992 .

Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay.

M. Hershfield, D. Bolognesi, T. Matthews, 1988, AIDS research and human retroviruses.

Interaction between thehumanT-cell lymphotropic virus type"'B envelope glycoprotein gpl20andthesurface antigen CD4: Roleofcarbohydrate inbinding andcell fusion

D. Bolognesi, T. Matthews, K. Weinhold, 1987 .

Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4.

J. Culp, M. Rosenberg, R. Sweet, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Interspecies reactivity of type C and D retrovirus p 15E and p 15C proteins.

D. Bolognesi, T. Matthews, H. Thiel, 1981, Virology.

Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

D. Bigner, T. Matthews, H. Furthmayr, 1983, Cancer research.

Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues

Brian W. Metcalf, Michael L. Moore, C. Debouck, 1990, Nature.

Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity.

T. Matthews, J. Weinberg, D. Granger, 1994, The Journal of infectious diseases.

Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity

R. Doms, J. Hoxie, C. Labranche, 1999, Journal of Virology.

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

A J Langlois, J. Ghrayeb, M. Robert-Guroff, 1986, Science.

Renal tubular antigens in regenerative epithelium and renal carcinoma.

T. Matthews, S. Fleming, 1987, British journal of urology.

Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus.

J. Ihle, D. Bolognesi, T. Matthews, 1984, Virology.

Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors

T. Matthews, K. Weinhold, C. Perno, 1991 .

Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.

T. Matthews, K. Weinhold, C. Perno, 1991, Blood.

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

D. Montefiori, M. Mulligan, R. Belshe, 2001, Vaccine.

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion

D. Bolognesi, T. Matthews, C. McDanal, 1995, Journal of virology.

Leiomyosarcoma of soft tissue and pulmonary metastasis, both with osteoclast-like giant cells.

T. Matthews, C. Fisher, 1994, Journal of clinical pathology.

Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes

M. Malim, B. Cullen, T. Matthews, 1991, The Journal of experimental medicine.

Comparison of the use of antibodies to alpha smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis.

T. Matthews, M. Sheppard, D. Hornall, 1993, Journal of clinical pathology.

Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.

W. J. Johnson, H. Koprowski, T. Matthews, 1986, Journal of immunology.

Efficacy of intravenous gamma globulin in autoimmune-mediated pediatric blood dyscrasias.

J. Kurtzberg, H. Friedman, T. Matthews, 1987, The American journal of medicine.

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.

T. Oas, E. Hunter, T. Matthews, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4

M. Skinner, D. Bolognesi, T. Matthews, 1988, Journal of virology.

In Vitro Translation of the Two RNAs of Nodamura Virus, a Novel Mammalian Virus with a Divided Genome

P. Kaesberg, R. Rueckert, T. Matthews, 1978, Journal of virology.

Oligosaccharide‐mediated interactions of the envelope glycoprotein gp120 of HIV‐1 that are independent of CD4 recognition

S. Thiel, C. Haslett, A. M. Lawson, 1989, AIDS.

Intracellular cleavage of an SSV coded gag-related protein.

T. Matthews, K. Weinhold, F. Weiland, 1982, Virology.

Clonal isolate of the simian sarcoma virus codes for a Gag-related 65,000-dalton protein.

T. Graf, H. Beug, D. Bolognesi, 1981, Virology.

Structural Rearrangements in the Transmembrane Glycoprotein after Receptor Binding

D. Bolognesi, T. Matthews, M. Greenberg, 1994, Immunological reviews.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

M. Kieny, P. Fultz, F. Barré-Sinoussi, 1995, Journal of virology.

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

B. Korber, D. Montefiori, Steven Wolinsky, 1998, The Journal of infectious diseases.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

Michael Greenberg, Jain Chung, D. Bolognesi, 2004, Nature Reviews Drug Discovery.

A Dose-Ranging Study of a Prototype Synthetic HIV-1MN V3 Branched Peptide Vaccine

W. Koff, R. Belshe, T. Matthews, 1996 .

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

T. Oas, D. Bolognesi, T. Matthews, 1992, Proceedings of the National Academy of Sciences of the United States of America.

CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2.

R. Doms, J. Hoxie, M. Endres, 1998, Journal of reproductive immunology.

GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.

D. Tyler, H. Lyerly, D. Bolognesi, 1989, Journal of immunology.

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

A J Langlois, H. Lyerly, D. Bolognesi, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.

H. Lyerly, T. Matthews, K. Weinhold, 1987, AIDS research and human retroviruses.

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope.

R. Snyderman, B. Safai, D. Bolognesi, 1987, Proceedings of the National Academy of Sciences of the United States of America.

A hidden region in the third variable domain of HIV-1 IIIB gp120 identified by a monoclonal antibody.

J. Moore, R. Meloen, J. Laman, 1993, AIDS research and human retroviruses.

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates

M. Robert-Guroff, R. Gallo, T. Matthews, 1992, Journal of virology.

Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

R. Gallo, D. Bolognesi, T. Matthews, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

L. Arthur, T. Copeland, D. Bolognesi, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees

K. Steimer, S. Zolla-Pazner, M. Lubeck, 1998, Journal of Virology.

Regulated Expression Allows High Level Production and Secretion of HIV-1 gp120 Envelope Glycoprotein in Drosophila Schneider Cells

M. Rosenberg, T. Matthews, H. Johansen, 1991, Bio/Technology.

Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1

L. Sawyer, H. Lane, L. Arthur, 1996, Journal of virology.

Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

Barney S. Graham, Richard Sposto, D. Stablein, 1994 .

HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide.

L. Bacheler, M. Rayner, R. Pomerantz, 1990, AIDS research and human retroviruses.

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

M. Kieny, J. Excler, T. Matthews, 1995, AIDS research and human retroviruses.

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

M. Champe, G. Nakamura, J. Mercer, 1992, Journal of virology.

AZT inhibits HIV-1 replication in monocytes.

M. Skinner, D. Bolognesi, T. Matthews, 1988, Journal of acquired immune deficiency syndromes.

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection

B. Autran, J. Tartaglia, P. Chong, 1999 .

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

R. Siliciano, E. Paoletti, J. Mascola, 1998, The Journal of infectious diseases.

Neopterin production by HIV‐1–infected mononuclear phagocytes

T. Matthews, J. Weinberg, E. Rivadeneira, 1994, Journal of leukocyte biology.

Conversion of an Intmunogenic Human Immunodeficiency Virus ( HIV ) Envelope Synthetic Peptide to a Tolerogen in Chimpanzees by the Fusogenic Domain of HIV g l ~ l Envelope Protein

B. Haynes, L. Arthur, R. Scearce, 2003 .

Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.

D. Bolognesi, T. Matthews, K. Weinhold, 1985, Journal of the National Cancer Institute.

Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.

D. Bolognesi, T. Matthews, K. Weinhold, 1985, Journal of the National Cancer Institute.

Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A.

D. Bolognesi, T. Matthews, K. Weinhold, 1985, Journal of the National Cancer Institute.

Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor.

J. Lieberman, J. Margolick, T. Quinn, 1994, AIDS research and human retroviruses.

Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees.

M. Klein, T. Matthews, G. Dekaban, 1999, Virology.

Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

J. Berzofsky, B. Haynes, R. Scearce, 1989, Journal of immunology.

Transmission of human immunodeficiency virus to sexual partners of hemophiliacs

D. Bolognesi, T. Matthews, K. Weinhold, 1988, American journal of hematology.

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

R. Siliciano, D. Stablein, R. Belshe, 1993, The Lancet.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

R. Belshe, B. Graham, R. Sposto, 1994, JAMA.

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

T. Matthews, 1994, AIDS research and human retroviruses.

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

M Salgo, T. Kirkland, T. Matthews, 2006, AIDS research and human retroviruses.

Ability of the V3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization: Correlation of Neutralization Sensitivity, Growth in Macrophages, and Decreased Dependence on CD4

M. Malim, J. Hoxie, R. Means, 2001, Journal of Virology.

C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.

W. Blattner, J. Drummond, L. Arthur, 1990, AIDS research and human retroviruses.

ofHumanImmunodeficiency VirusType1and 2andSimian Immunodeficiency VirusIsolates

T. Matthews, G. Bansal, T. L. Stern, 1992 .

Purification of envelope glycoproteins of human T cell lymphotropic virus type I (HTLV-I) by affinity chromatography.

T. Matthews, M. E. Clark, M. Sarngadharan, 1987, Journal of virological methods.

Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates.

D. Lambert, T. Matthews, G. Dreyer, 1996, AIDS research and human retroviruses.

Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group

F. Newman, R. Belshe, P. Berman, 1996, Clinical and diagnostic laboratory immunology.

pulmonary lymphangioleiomyomatosis . smooth muscle actin and desmin in Comparison of the use of antibodies to alpha

T. Matthews, M. Sheppard, D. Hornall, 2022 .

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.

D. Montefiori, D. Stablein, M. McElrath, 2000, AIDS research and human retroviruses.

Identification of gp120 Regions Targeted by a Highly Potent Neutralizing Antiserum Elicited in a Chimpanzee Inoculated with a Primary Human Immunodeficiency Virus Type 1 Isolate

M. Cho, T. Matthews, Chin-Ho Chen, 2000, Journal of Virology.

Familial Hodgkin's disease a clinical and laboratory investigation

S. Bigner, M. Borowitz, T. Matthews, 1987, Cancer.

Isolate- and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques.

P. Earl, B. Moss, M. Robert-Guroff, 1989, AIDS Research and Human Retroviruses.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

B. Graham, F. Sinangil, J. Esterlitz, 1996, Annals of internal medicine.

Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160

G. Nakamura, J. Groopman, P. Berman, 1989, Journal of virology.

Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

H. Lyerly, M. Skinner, T. Matthews, 1988, AIDS research and human retroviruses.

Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction.

D. Bolognesi, T. Matthews, H. Thiel, 1981, Journal of immunology.

Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum.

D. Bolognesi, T. Matthews, H. Thiel, 1981, Journal of immunology.

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

R. Belshe, D. Francis, P. Berman, 1998, AIDS research and human retroviruses.

Design of an engineered N‐terminal HIV‐1 gp41 trimer with enhanced stability and potency

T. Matthews, Hidong Kim, J. J. Dwyer, 2008, Protein science : a publication of the Protein Society.

Ability of the V 3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization : Correlation of Neutralization Sensitivity , Growth in Macrophages , and Decreased Dependence on CD 4

M. Malim, J. Hoxie, R. Means, 2001 .

95- and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.

H. Jörnvall, T. Bergman, T. Matthews, 1988, Proceedings of the National Academy of Sciences of the United States of America.

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

W. Koff, R. Belshe, T. Matthews, 1996, The Journal of infectious diseases.

In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251.

D. Bolognesi, T. Matthews, K. Weinhold, 1991, AIDS research and human retroviruses.

EVIDENCE FOR HUMAN INFECTION WITH AN HTLV III/LAV-LIKE VIRUS IN CENTRAL AFRICA, 1959

R. Kodsi, D. Durack, A. Motulsky, 1986, The Lancet.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

D. Bolognesi, T. Matthews, M. Greenberg, 2004 .

Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

D. Stablein, M. McElrath, B. Graham, 1998, The Journal of infectious diseases.

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans

D. Montefiori, D. Stablein, M. McElrath, 1994 .

Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.

S. Zolla-Pazner, T. Matthews, S. Karwowska, 1995, AIDS research and human retroviruses.

Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.

B. Haynes, M. A. Moody, R. Scearce, 1993, Transactions of the Association of American Physicians.

Preparation of autologous antiserum against SSV nonproducer cells and its partial characterization.

J. Iglehart, T. Matthews, H. Thiel, 1981, Virology.

Characterization of antigens in SSV nonproducer cells.

D. Bolognesi, T. Matthews, H. Thiel, 1981, Haematology and blood transfusion.

Identification of a 20,000-dalton protein in SSV-transformed nonproducer cells.

T. Matthews, K. Weinhold, H. Thiel, 1981, Virology.

Induction and Characterization of Neutralizing Antibodies against a Human Immunodeficiency Virus Type 1 Primary Isolate

Lei Jin, T. Matthews, Chin-Ho Chen, 2001, Journal of Virology.

Synthetic Inhibitors of HIV‐1 Protease Block Processing of Pr55gag and Pr160gag‐po1 Polyproteins in Infected T Lymphocytes

D. Lambert, T. Matthews, T. Meek, 1990 .

Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41

T. Matthews, D. Shugars, C. Wild, 1996, Journal of virology.